Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.

O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752.

PMID:
24249383
2.

Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14.

3.

Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.

Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ.

Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20.

4.

Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.

5.

Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.

Hagberg Thulin M, Jennbacken K, Damber JE, Welén K.

Clin Exp Metastasis. 2014 Mar;31(3):269-83. doi: 10.1007/s10585-013-9626-1. Epub 2013 Dec 1.

6.

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Feb;74(3):225-34. doi: 10.1002/pros.22744. Epub 2013 Oct 16.

PMID:
24132762
7.

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.

Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH.

Yonsei Med J. 2015 Sep;56(5):1206-12. doi: 10.3349/ymj.2015.56.5.1206.

8.

The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.

Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW.

BMC Cancer. 2017 Mar 1;17(1):163. doi: 10.1186/s12885-017-3100-4.

9.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Cancer. 2013 Aug 15;119(16):2990-8. doi: 10.1002/cncr.28102. Epub 2013 May 29.

10.

Characterising the castration-resistant prostate cancer population: a systematic review.

Kirby M, Hirst C, Crawford ED.

Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. Review.

PMID:
21995694
12.

Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?

Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR.

Prostate. 2013 May;73(7):743-53. doi: 10.1002/pros.22618. Epub 2013 Jan 28.

PMID:
23359479
13.

High expression of the Met receptor in prostate cancer metastasis to bone.

Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF.

Urology. 2002 Dec;60(6):1113-7.

PMID:
12475693
14.

Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.

Crnalic S, Hörnberg E, Wikström P, Lerner UH, Tieva A, Svensson O, Widmark A, Bergh A.

Endocr Relat Cancer. 2010 Oct 5;17(4):885-95. doi: 10.1677/ERC-10-0059. Print 2010 Dec.

15.

Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.

Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H.

Diagn Pathol. 2012 Sep 24;7:127. doi: 10.1186/1746-1596-7-127.

16.

Osteoprotegerin and rank ligand expression in prostate cancer.

Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL.

Urology. 2001 Apr;57(4):611-6.

PMID:
11306358
17.

The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.

Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, Patel O.

Cancer Med. 2014 Apr;3(2):245-51. doi: 10.1002/cam4.189. Epub 2014 Jan 27.

18.

The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.

Valdez CD, Kunju L, Daignault S, Wojno KJ, Day ML.

Prostate. 2013 Dec;73(16):1776-85. doi: 10.1002/pros.22715. Epub 2013 Sep 4.

19.

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.

Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G.

Prostate. 2014 Feb;74(3):297-305. doi: 10.1002/pros.22750.

PMID:
24395565
20.

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.

Clin Cancer Res. 2003 Jul;9(7):2587-97.

Supplemental Content

Support Center